About
Neurodegenerative Therapies
Areas of Focus
Categories
DiagnosticsBiologics & BiopharmaceuticalAntibodyBoston & New England
Team (25)
Andre Strydom, MD, PhD
ProMIS Neurosciences
team_member
Cheryl Wellington, PhD
ProMIS Neurosciences
team_member
Daniel Geffken
Chief Financial Officer
ProMIS Neurosciences
executive
David Wishart, Ph.D.
Chief Physics Officer
ProMIS Neurosciences
team_member
Dennis Chen, Ph.D.
Head of Manufacturing – Senior Consultant
ProMIS Neurosciences
team_member
Dr. Alain Dagher, MD, FRCP
ProMIS Neurosciences
team_member
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
168
By Phase
PHASE1: 2
By Status
RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06750432Lead Sponsor
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
PHASE1Recruiting
128 participants
Started: Dec 13, 2024 · Completed: Dec 31, 2026
NCT06105528Lead Sponsor
A Phase 1a Study of PMN310 In Healthy Volunteers
PHASE1Completed
40 participants
Started: Nov 18, 2023 · Completed: Jul 31, 2024
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...